Funding for this research was provided by:
European Commission (018947)
Academy of Finland (139635 and 118065, 297338 and 307247)
Novo Nordisk Fonden (NNF17OC0026062)
NWO (NWO-VIDI 016.178.056, RFBR 047.017.043, 184.021.007 and 184033111, NWO-VIDI 864.13.013)
European Community's Seventh Framework Programme (HEALTH-F4-2007-201413)
Netherlands Heart Foundation (IN-CONTROL CVON grant 2012-03)
European Research Council (715772)
Received: 12 April 2020
Accepted: 29 June 2020
First Online: 16 July 2020
Ethics approval and consent to participate
: Both RS and ERF were approved by the Medical Ethics committee of the Erasmus Medical Center and all participants gave informed consent for participation in the study and for evaluation of the available information from their physicians.LLDEEP was approved by the ethics committee of the University Medical Center Groningen and all participants signed an informed consent prior to enrolment.The FINRISK 1997 study was approved by the Ethical Committee of the National Public Health Institute, while the DILGOM study was approved by the Coordinating Ethical Committee of the Hospital District of Helsinki and Uusimaa. All participants have signed an informed consent, allowing the use of their data and samples for studying environmental and genetic risk factors of chronic diseases.The Ethics Committee of the University of Uppsala approved the study and the participants gave informed consent (approval number 00–419).
: Not applicable.
: All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. VS has participated in a conference trip sponsored by Novo Nordisk and received a modest honorarium from the same source for participating in an advisory board meeting. He also has ongoing research collaboration with Bayer Ltd.